DVAX - Dynavax Technologies Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Dynavax Technologies Corporation

2929 Seventh Street
Suite 100
Berkeley, CA 94710
United States
510-848-5100
http://www.dynavax.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees170

Key Executives

NameTitlePayExercisedYear Born
Mr. Eddie GrayCEO & Director602kN/A1959
Dr. Dennis A. CarsonCo-Founder & Director40kN/A1947
Mr. Michael S. OstrachCFO, Chief Bus. Officer & Sr. VP427kN/A1952
Mr. David F. NovackSr. VP of Operations and Quality388.25kN/A1962
Dr. Robert L. CoffmanChief Scientific Officer and Sr. VP468.8kN/A1947
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer. Its product candidates also comprise AZD1419, which is in Phase II clinical trial for the treatment of asthma; DV230F that is in preclinical stage for the treatment of liver tumors; and DV1001, a TLR 7&8 agonist, which is in preclinical stage for oncology. It has collaboration and license agreements with AstraZeneca AB to develop AZD1419 for the treatment of asthma; and Merck & Co. to develop SD-101 for various immuno-oncology therapies. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Berkeley, California.

Corporate Governance

Dynavax Technologies Corporation’s ISS Governance QualityScore as of April 1, 2018 is 7. The pillar scores are Audit: 2; Board: 3; Shareholder Rights: 9; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.